Therapeutic options for the management of influenza
Identifieur interne : 000A21 ( Istex/Corpus ); précédent : 000A20; suivant : 000A22Therapeutic options for the management of influenza
Auteurs : Michael G. Ison ; Frederick G. HaydenSource :
- Current Opinion in Pharmacology [ 1471-4892 ] ; 2001.
English descriptors
- KwdEn :
- Teeft :
- Active metabolite, Acute influenza, Adverse effects, Adverse events, Amantadine, Amantadine hydrochloride, Antibiotic, Antimicrob, Antimicrob agents chemother, Antimicrobial agents, Antiviral, Antiviral activity, Antiviral drug resistance, Available agents, Available neuraminidase inhibitors, Bioavailability, Chemother, Clin, Clin pharmacokin, Clinical pharmacokinetics, Clinical trials, Combination therapy, Concomitant vaccination, Control subjects, Creatinine clearance, Drug interactions, Elderly nursing home residents, Excellent overview, Febrile patients, Global neuraminidase inhibitor susceptibility network, Glomerular filtration, Guanosine analog, Hayden, Healthy adults, Healthy volunteers, Hemagglutinin, Household contacts, Illness duration, Immunocompromised, Immunocompromised child, Immunocompromised hosts, Important differences, Infectious diseases, Influenza, Influenza hayden, Influenza infections, Influenza virus, Influenza viruses, Inhaled, Inhaled zanamivir, Inhibitor, Interscience conference, Largest study, Median time, Moderate nausea, Neuraminidase, Neuraminidase inhibitor resistance, Neuraminidase inhibitor zanamivir, Neuraminidase inhibitors, Normal activity, Oral administration, Oral oseltamivir, Oral oseltamivir treatment, Oseltamivir, Oseltamivir carboxylate, Overview, Placebo, Placebo days, Plasma elimination, Plasma protein binding, Pregnant women, Pulmonary disease, Randomized, Regimen findings, Relief medications, Renal impairment, Representative studies, Resistant virus, Respiratory tract, Respiratory tract complications, Ribavirin, Ribavirin triphosphate, Rimantadine, September toronto, Serious toxicity, Several studies, Severe influenza, Significant drug interactions, Symptom, Symptom alleviation, Symptoms days, Therapeutic effectiveness, Therapeutic efficacy, Therapeutic options, Tuberculosis chest, Tubular secretion, Uncomplicated influenza, Usual activities, Usual activity, Viral, Viral neuraminidase, Virus infection, Virus infections, Virus strain numbers, Years inhaled, Zanamivir, Zanamivir treatment studies.
Abstract
Abstract: Over the past few years a novel class of antiviral agents, the neuraminidase inhibitors, has been found to be safe and effective in the prevention and treatment of influenza. Previously available agents, the M2 inhibitors amantadine and rimantadine, could only be used to treat influenza A infections and resistance develops rapidly. Zanamivir (Relenza®) and oseltamivir (Tamiflu™), the two clinically available neuraminidase inhibitors, are effective for treating both influenza A and B infections in adults and children and have also been shown to reduce the frequency of antibiotic-requiring complications of influenza infections. Inhaled zanamivir has shown benefit in treating acute influenza with mild to moderate underlying asthma or chronic obstructive pulmonary disease. Studies are needed to examine the use of these agents, alone or in combination with M2 inhibitors or ribavirin, in the management of severe infections in hospitalized patients and immunocompromised hosts. Studies are also needed to address other groups at increased risk for influenza complications, such as pregnant women and children below one year of age.
Url:
DOI: 10.1016/S1471-4892(01)00084-4
Links to Exploration step
ISTEX:E322701CE07DFA8A0DF19075A00CA8FD6F0E9CA4Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic options for the management of influenza</title><author><name sortKey="Ison, Michael G" sort="Ison, Michael G" uniqKey="Ison M" first="Michael G" last="Ison">Michael G. Ison</name><affiliation><mods:affiliation>University of Virginia Health Sciences Center, Division of Infectious Diseases, Charlottesville, Virginia 22908 USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: mgison@alumni.grinnell.edu</mods:affiliation></affiliation></author><author><name sortKey="Hayden, Frederick G" sort="Hayden, Frederick G" uniqKey="Hayden F" first="Frederick G" last="Hayden">Frederick G. Hayden</name><affiliation><mods:affiliation>University of Virginia Health Sciences Center, Division of Infectious Diseases, Charlottesville, Virginia 22908 USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E322701CE07DFA8A0DF19075A00CA8FD6F0E9CA4</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1016/S1471-4892(01)00084-4</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-2R3399BL-9/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000A21</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000A21</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Therapeutic options for the management of influenza</title><author><name sortKey="Ison, Michael G" sort="Ison, Michael G" uniqKey="Ison M" first="Michael G" last="Ison">Michael G. Ison</name><affiliation><mods:affiliation>University of Virginia Health Sciences Center, Division of Infectious Diseases, Charlottesville, Virginia 22908 USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: mgison@alumni.grinnell.edu</mods:affiliation></affiliation></author><author><name sortKey="Hayden, Frederick G" sort="Hayden, Frederick G" uniqKey="Hayden F" first="Frederick G" last="Hayden">Frederick G. Hayden</name><affiliation><mods:affiliation>University of Virginia Health Sciences Center, Division of Infectious Diseases, Charlottesville, Virginia 22908 USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Current Opinion in Pharmacology</title><title level="j" type="abbrev">COPHAR</title><idno type="ISSN">1471-4892</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2001">2001</date><biblScope unit="volume">1</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="482">482</biblScope><biblScope unit="page" to="490">490</biblScope></imprint><idno type="ISSN">1471-4892</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1471-4892</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amantadine</term><term>Influenza</term><term>M2 Inhibitor</term><term>Neuraminidase inhibitor</term><term>Oseltamivir</term><term>Pharmaceutical Science</term><term>Pharmacology</term><term>Ribavirin</term><term>Rimantadine</term><term>Virology</term><term>Zanamivir</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Active metabolite</term><term>Acute influenza</term><term>Adverse effects</term><term>Adverse events</term><term>Amantadine</term><term>Amantadine hydrochloride</term><term>Antibiotic</term><term>Antimicrob</term><term>Antimicrob agents chemother</term><term>Antimicrobial agents</term><term>Antiviral</term><term>Antiviral activity</term><term>Antiviral drug resistance</term><term>Available agents</term><term>Available neuraminidase inhibitors</term><term>Bioavailability</term><term>Chemother</term><term>Clin</term><term>Clin pharmacokin</term><term>Clinical pharmacokinetics</term><term>Clinical trials</term><term>Combination therapy</term><term>Concomitant vaccination</term><term>Control subjects</term><term>Creatinine clearance</term><term>Drug interactions</term><term>Elderly nursing home residents</term><term>Excellent overview</term><term>Febrile patients</term><term>Global neuraminidase inhibitor susceptibility network</term><term>Glomerular filtration</term><term>Guanosine analog</term><term>Hayden</term><term>Healthy adults</term><term>Healthy volunteers</term><term>Hemagglutinin</term><term>Household contacts</term><term>Illness duration</term><term>Immunocompromised</term><term>Immunocompromised child</term><term>Immunocompromised hosts</term><term>Important differences</term><term>Infectious diseases</term><term>Influenza</term><term>Influenza hayden</term><term>Influenza infections</term><term>Influenza virus</term><term>Influenza viruses</term><term>Inhaled</term><term>Inhaled zanamivir</term><term>Inhibitor</term><term>Interscience conference</term><term>Largest study</term><term>Median time</term><term>Moderate nausea</term><term>Neuraminidase</term><term>Neuraminidase inhibitor resistance</term><term>Neuraminidase inhibitor zanamivir</term><term>Neuraminidase inhibitors</term><term>Normal activity</term><term>Oral administration</term><term>Oral oseltamivir</term><term>Oral oseltamivir treatment</term><term>Oseltamivir</term><term>Oseltamivir carboxylate</term><term>Overview</term><term>Placebo</term><term>Placebo days</term><term>Plasma elimination</term><term>Plasma protein binding</term><term>Pregnant women</term><term>Pulmonary disease</term><term>Randomized</term><term>Regimen findings</term><term>Relief medications</term><term>Renal impairment</term><term>Representative studies</term><term>Resistant virus</term><term>Respiratory tract</term><term>Respiratory tract complications</term><term>Ribavirin</term><term>Ribavirin triphosphate</term><term>Rimantadine</term><term>September toronto</term><term>Serious toxicity</term><term>Several studies</term><term>Severe influenza</term><term>Significant drug interactions</term><term>Symptom</term><term>Symptom alleviation</term><term>Symptoms days</term><term>Therapeutic effectiveness</term><term>Therapeutic efficacy</term><term>Therapeutic options</term><term>Tuberculosis chest</term><term>Tubular secretion</term><term>Uncomplicated influenza</term><term>Usual activities</term><term>Usual activity</term><term>Viral</term><term>Viral neuraminidase</term><term>Virus infection</term><term>Virus infections</term><term>Virus strain numbers</term><term>Years inhaled</term><term>Zanamivir</term><term>Zanamivir treatment studies</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Over the past few years a novel class of antiviral agents, the neuraminidase inhibitors, has been found to be safe and effective in the prevention and treatment of influenza. Previously available agents, the M2 inhibitors amantadine and rimantadine, could only be used to treat influenza A infections and resistance develops rapidly. Zanamivir (Relenza®) and oseltamivir (Tamiflu™), the two clinically available neuraminidase inhibitors, are effective for treating both influenza A and B infections in adults and children and have also been shown to reduce the frequency of antibiotic-requiring complications of influenza infections. Inhaled zanamivir has shown benefit in treating acute influenza with mild to moderate underlying asthma or chronic obstructive pulmonary disease. Studies are needed to examine the use of these agents, alone or in combination with M2 inhibitors or ribavirin, in the management of severe infections in hospitalized patients and immunocompromised hosts. Studies are also needed to address other groups at increased risk for influenza complications, such as pregnant women and children below one year of age.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>zanamivir</json:string><json:string>amantadine</json:string><json:string>neuraminidase</json:string><json:string>rimantadine</json:string><json:string>oseltamivir</json:string><json:string>influenza</json:string><json:string>placebo</json:string><json:string>inhaled</json:string><json:string>hayden</json:string><json:string>ribavirin</json:string><json:string>viral</json:string><json:string>antiviral</json:string><json:string>randomized</json:string><json:string>inhaled zanamivir</json:string><json:string>neuraminidase inhibitors</json:string><json:string>inhibitor</json:string><json:string>acute influenza</json:string><json:string>overview</json:string><json:string>hemagglutinin</json:string><json:string>immunocompromised</json:string><json:string>antimicrob</json:string><json:string>adverse effects</json:string><json:string>antimicrob agents chemother</json:string><json:string>clin</json:string><json:string>chemother</json:string><json:string>bioavailability</json:string><json:string>antibiotic</json:string><json:string>amantadine hydrochloride</json:string><json:string>drug interactions</json:string><json:string>placebo days</json:string><json:string>antiviral activity</json:string><json:string>oral oseltamivir</json:string><json:string>healthy adults</json:string><json:string>regimen findings</json:string><json:string>influenza hayden</json:string><json:string>influenza virus</json:string><json:string>resistant virus</json:string><json:string>clin pharmacokin</json:string><json:string>years inhaled</json:string><json:string>antimicrobial agents</json:string><json:string>therapeutic options</json:string><json:string>moderate nausea</json:string><json:string>available agents</json:string><json:string>uncomplicated influenza</json:string><json:string>influenza viruses</json:string><json:string>september toronto</json:string><json:string>immunocompromised hosts</json:string><json:string>interscience conference</json:string><json:string>usual activities</json:string><json:string>adverse events</json:string><json:string>pulmonary disease</json:string><json:string>viral neuraminidase</json:string><json:string>normal activity</json:string><json:string>severe influenza</json:string><json:string>median time</json:string><json:string>symptom</json:string><json:string>control subjects</json:string><json:string>elderly nursing home residents</json:string><json:string>respiratory tract</json:string><json:string>symptoms days</json:string><json:string>plasma protein binding</json:string><json:string>symptom alleviation</json:string><json:string>oseltamivir carboxylate</json:string><json:string>immunocompromised child</json:string><json:string>global neuraminidase inhibitor susceptibility network</json:string><json:string>creatinine clearance</json:string><json:string>clinical trials</json:string><json:string>significant drug interactions</json:string><json:string>concomitant vaccination</json:string><json:string>renal impairment</json:string><json:string>zanamivir treatment studies</json:string><json:string>respiratory tract complications</json:string><json:string>serious toxicity</json:string><json:string>active metabolite</json:string><json:string>oral administration</json:string><json:string>plasma elimination</json:string><json:string>usual activity</json:string><json:string>tubular secretion</json:string><json:string>important differences</json:string><json:string>illness duration</json:string><json:string>glomerular filtration</json:string><json:string>relief medications</json:string><json:string>febrile patients</json:string><json:string>ribavirin triphosphate</json:string><json:string>virus strain numbers</json:string><json:string>virus infection</json:string><json:string>excellent overview</json:string><json:string>antiviral drug resistance</json:string><json:string>representative studies</json:string><json:string>clinical pharmacokinetics</json:string><json:string>several studies</json:string><json:string>therapeutic effectiveness</json:string><json:string>tuberculosis chest</json:string><json:string>combination therapy</json:string><json:string>guanosine analog</json:string><json:string>infectious diseases</json:string><json:string>therapeutic efficacy</json:string><json:string>household contacts</json:string><json:string>pregnant women</json:string><json:string>influenza infections</json:string><json:string>available neuraminidase inhibitors</json:string><json:string>neuraminidase inhibitor resistance</json:string><json:string>neuraminidase inhibitor zanamivir</json:string><json:string>virus infections</json:string><json:string>largest study</json:string><json:string>healthy volunteers</json:string><json:string>oral oseltamivir treatment</json:string></teeft></keywords><author><json:item><name>Michael G Ison</name><affiliations><json:string>University of Virginia Health Sciences Center, Division of Infectious Diseases, Charlottesville, Virginia 22908 USA</json:string><json:string>E-mail: mgison@alumni.grinnell.edu</json:string></affiliations></json:item><json:item><name>Frederick G Hayden</name><affiliations><json:string>University of Virginia Health Sciences Center, Division of Infectious Diseases, Charlottesville, Virginia 22908 USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Anti-infectives</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Influenza</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Neuraminidase inhibitor</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>M2 Inhibitor</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Amantadine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Rimantadine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Zanamivir</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Oseltamivir</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Ribavirin</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Pharmacology</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Pharmaceutical Science</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Virology</value></json:item></subject><arkIstex>ark:/67375/6H6-2R3399BL-9</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Review article</json:string></originalGenre><abstract>Abstract: Over the past few years a novel class of antiviral agents, the neuraminidase inhibitors, has been found to be safe and effective in the prevention and treatment of influenza. Previously available agents, the M2 inhibitors amantadine and rimantadine, could only be used to treat influenza A infections and resistance develops rapidly. Zanamivir (Relenza®) and oseltamivir (Tamiflu™), the two clinically available neuraminidase inhibitors, are effective for treating both influenza A and B infections in adults and children and have also been shown to reduce the frequency of antibiotic-requiring complications of influenza infections. Inhaled zanamivir has shown benefit in treating acute influenza with mild to moderate underlying asthma or chronic obstructive pulmonary disease. Studies are needed to examine the use of these agents, alone or in combination with M2 inhibitors or ribavirin, in the management of severe infections in hospitalized patients and immunocompromised hosts. Studies are also needed to address other groups at increased risk for influenza complications, such as pregnant women and children below one year of age.</abstract><qualityIndicators><score>9.016</score><pdfWordCount>6301</pdfWordCount><pdfCharCount>42607</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>9</pdfPageCount><pdfPageSize>595 x 842 pts (A4)</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>168</abstractWordCount><abstractCharCount>1148</abstractCharCount><keywordCount>12</keywordCount></qualityIndicators><title>Therapeutic options for the management of influenza</title><pmid><json:string>11764774</json:string></pmid><pii><json:string>S1471-4892(01)00084-4</json:string></pii><genre><json:string>review-article</json:string></genre><host><title>Current Opinion in Pharmacology</title><language><json:string>unknown</json:string></language><publicationDate>2001</publicationDate><issn><json:string>1471-4892</json:string></issn><pii><json:string>S1471-4892(00)X0005-7</json:string></pii><volume>1</volume><issue>5</issue><pages><first>482</first><last>490</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2001</json:string><json:string>1918</json:string></date><geogName></geogName><orgName><json:string>Forest Pharmaceuticals Inc.</json:string><json:string>Elsevier Science Ltd.</json:string><json:string>Division of Infectious Diseases</json:string><json:string>Virginia Health Sciences Center</json:string><json:string>ICN Pharmaceuticals Inc.</json:string><json:string>Research Triangle Park, North Carolina</json:string><json:string>Endo Pharmaceuticals Inc.</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Hong Kong</json:string><json:string>Anecdotal</json:string></persName><placeName><json:string>Bangkok</json:string><json:string>Kumamoto</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>[61]</json:string><json:string>[65,66]</json:string><json:string>[34]</json:string><json:string>[20,21,25]</json:string><json:string>[29]</json:string><json:string>[33]</json:string><json:string>[39]</json:string><json:string>[70]</json:string><json:string>[32]</json:string><json:string>[41,56]</json:string><json:string>[63,64]</json:string><json:string>[27]</json:string><json:string>[63,67]</json:string><json:string>[9,10]</json:string><json:string>[42]</json:string><json:string>[59]</json:string><json:string>[40,41]</json:string><json:string>[41]</json:string><json:string>[69]</json:string><json:string>[51]</json:string><json:string>[68]</json:string><json:string>[19]</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-2R3399BL-9</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - pharmacology & pharmacy</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - pharmacology & pharmacy</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Pharmacology, Toxicology and Pharmaceutics</json:string><json:string>3 - Drug Discovery</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Pharmacology, Toxicology and Pharmaceutics</json:string><json:string>3 - Pharmacology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string><json:string>4 - pharmacologie. traitements medicamenteux</json:string></inist></categories><publicationDate>2001</publicationDate><copyrightDate>2001</copyrightDate><doi><json:string>10.1016/S1471-4892(01)00084-4</json:string></doi><id>E322701CE07DFA8A0DF19075A00CA8FD6F0E9CA4</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-2R3399BL-9/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-2R3399BL-9/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-2R3399BL-9/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Therapeutic options for the management of influenza</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>©2001 Elsevier Science Ltd</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</p></availability><date>2001</date></publicationStmt><notesStmt><note type="review-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note type="content">Section title: Review</note><note type="content">Table 1: Representative studies of amantadine treatment in acute influenza.</note><note type="content">Table 2: Representative studies of rimantadine treatment in acute influenza.</note><note type="content">Table 3: Zanamivir therapy trials.</note><note type="content">Table 4: Oseltamivir therapy trials.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Therapeutic options for the management of influenza</title><author xml:id="author-0000"><persName><forename type="first">Michael G</forename><surname>Ison</surname></persName><email>mgison@alumni.grinnell.edu</email><affiliation>University of Virginia Health Sciences Center, Division of Infectious Diseases, Charlottesville, Virginia 22908 USA</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Frederick G</forename><surname>Hayden</surname></persName><affiliation>University of Virginia Health Sciences Center, Division of Infectious Diseases, Charlottesville, Virginia 22908 USA</affiliation></author><idno type="istex">E322701CE07DFA8A0DF19075A00CA8FD6F0E9CA4</idno><idno type="ark">ark:/67375/6H6-2R3399BL-9</idno><idno type="DOI">10.1016/S1471-4892(01)00084-4</idno><idno type="PII">S1471-4892(01)00084-4</idno></analytic><monogr><title level="j">Current Opinion in Pharmacology</title><title level="j" type="abbrev">COPHAR</title><idno type="pISSN">1471-4892</idno><idno type="PII">S1471-4892(00)X0005-7</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2001"></date><biblScope unit="volume">1</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="482">482</biblScope><biblScope unit="page" to="490">490</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2001</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: Over the past few years a novel class of antiviral agents, the neuraminidase inhibitors, has been found to be safe and effective in the prevention and treatment of influenza. Previously available agents, the M2 inhibitors amantadine and rimantadine, could only be used to treat influenza A infections and resistance develops rapidly. Zanamivir (Relenza®) and oseltamivir (Tamiflu™), the two clinically available neuraminidase inhibitors, are effective for treating both influenza A and B infections in adults and children and have also been shown to reduce the frequency of antibiotic-requiring complications of influenza infections. Inhaled zanamivir has shown benefit in treating acute influenza with mild to moderate underlying asthma or chronic obstructive pulmonary disease. Studies are needed to examine the use of these agents, alone or in combination with M2 inhibitors or ribavirin, in the management of severe infections in hospitalized patients and immunocompromised hosts. Studies are also needed to address other groups at increased risk for influenza complications, such as pregnant women and children below one year of age.</p></abstract><textClass><keywords scheme="keyword"><list><head>article-category</head><item><term>Anti-infectives</term></item></list></keywords></textClass><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Influenza</term></item><item><term>Neuraminidase inhibitor</term></item><item><term>M2 Inhibitor</term></item><item><term>Amantadine</term></item><item><term>Rimantadine</term></item><item><term>Zanamivir</term></item><item><term>Oseltamivir</term></item><item><term>Ribavirin</term></item></list></keywords></textClass><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Pharmacology</term></item><item><term>Pharmaceutical Science</term></item><item><term>Virology</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2001">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-2R3399BL-9/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: ce:floats; body; tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="rev" xml:lang="en"><item-info><jid>COPHAR</jid><aid>00000084</aid><ce:pii>S1471-4892(01)00084-4</ce:pii><ce:doi>10.1016/S1471-4892(01)00084-4</ce:doi><ce:copyright type="full-transfer" year="2001">Elsevier Science Ltd</ce:copyright><ce:doctopics><ce:doctopic><ce:text>Anti-infectives</ce:text></ce:doctopic></ce:doctopics></item-info><head><ce:dochead><ce:textfn>Review</ce:textfn></ce:dochead><ce:title>Therapeutic options for the management of influenza</ce:title><ce:author-group><ce:author><ce:given-name>Michael G</ce:given-name><ce:surname>Ison</ce:surname><ce:e-address type="email">mgison@alumni.grinnell.edu</ce:e-address></ce:author><ce:author><ce:given-name>Frederick G</ce:given-name><ce:surname>Hayden</ce:surname></ce:author><ce:affiliation><ce:textfn>University of Virginia Health Sciences Center, Division of Infectious Diseases, Charlottesville, Virginia 22908 USA</ce:textfn></ce:affiliation></ce:author-group><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>Over the past few years a novel class of antiviral agents, the neuraminidase inhibitors, has been found to be safe and effective in the prevention and treatment of influenza. Previously available agents, the M2 inhibitors amantadine and rimantadine, could only be used to treat influenza A infections and resistance develops rapidly. Zanamivir (Relenza®) and oseltamivir (Tamiflu™), the two clinically available neuraminidase inhibitors, are effective for treating both influenza A and B infections in adults and children and have also been shown to reduce the frequency of antibiotic-requiring complications of influenza infections. Inhaled zanamivir has shown benefit in treating acute influenza with mild to moderate underlying asthma or chronic obstructive pulmonary disease. Studies are needed to examine the use of these agents, alone or in combination with M2 inhibitors or ribavirin, in the management of severe infections in hospitalized patients and immunocompromised hosts. Studies are also needed to address other groups at increased risk for influenza complications, such as pregnant women and children below one year of age.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords class="keyword"><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Influenza</ce:text></ce:keyword><ce:keyword><ce:text>Neuraminidase inhibitor</ce:text></ce:keyword><ce:keyword><ce:text>M2 Inhibitor</ce:text></ce:keyword><ce:keyword><ce:text>Amantadine</ce:text></ce:keyword><ce:keyword><ce:text>Rimantadine</ce:text></ce:keyword><ce:keyword><ce:text>Zanamivir</ce:text></ce:keyword><ce:keyword><ce:text>Oseltamivir</ce:text></ce:keyword><ce:keyword><ce:text>Ribavirin</ce:text></ce:keyword></ce:keywords><ce:keywords class="idt"><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Pharmacology</ce:text></ce:keyword><ce:keyword><ce:text>Pharmaceutical Science</ce:text></ce:keyword><ce:keyword><ce:text>Virology</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Therapeutic options for the management of influenza</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Therapeutic options for the management of influenza</title></titleInfo><name type="personal"><namePart type="given">Michael G</namePart><namePart type="family">Ison</namePart><affiliation>University of Virginia Health Sciences Center, Division of Infectious Diseases, Charlottesville, Virginia 22908 USA</affiliation><affiliation>E-mail: mgison@alumni.grinnell.edu</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Frederick G</namePart><namePart type="family">Hayden</namePart><affiliation>University of Virginia Health Sciences Center, Division of Infectious Diseases, Charlottesville, Virginia 22908 USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="Review article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">2001</dateIssued><copyrightDate encoding="w3cdtf">2001</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: Over the past few years a novel class of antiviral agents, the neuraminidase inhibitors, has been found to be safe and effective in the prevention and treatment of influenza. Previously available agents, the M2 inhibitors amantadine and rimantadine, could only be used to treat influenza A infections and resistance develops rapidly. Zanamivir (Relenza®) and oseltamivir (Tamiflu™), the two clinically available neuraminidase inhibitors, are effective for treating both influenza A and B infections in adults and children and have also been shown to reduce the frequency of antibiotic-requiring complications of influenza infections. Inhaled zanamivir has shown benefit in treating acute influenza with mild to moderate underlying asthma or chronic obstructive pulmonary disease. Studies are needed to examine the use of these agents, alone or in combination with M2 inhibitors or ribavirin, in the management of severe infections in hospitalized patients and immunocompromised hosts. Studies are also needed to address other groups at increased risk for influenza complications, such as pregnant women and children below one year of age.</abstract><note type="content">Section title: Review</note><note type="content">Table 1: Representative studies of amantadine treatment in acute influenza.</note><note type="content">Table 2: Representative studies of rimantadine treatment in acute influenza.</note><note type="content">Table 3: Zanamivir therapy trials.</note><note type="content">Table 4: Oseltamivir therapy trials.</note><subject><genre>article-category</genre><topic>Anti-infectives</topic></subject><subject lang="en"><genre>Keywords</genre><topic>Influenza</topic><topic>Neuraminidase inhibitor</topic><topic>M2 Inhibitor</topic><topic>Amantadine</topic><topic>Rimantadine</topic><topic>Zanamivir</topic><topic>Oseltamivir</topic><topic>Ribavirin</topic></subject><subject lang="en"><genre>Keywords</genre><topic>Pharmacology</topic><topic>Pharmaceutical Science</topic><topic>Virology</topic></subject><relatedItem type="host"><titleInfo><title>Current Opinion in Pharmacology</title></titleInfo><titleInfo type="abbreviated"><title>COPHAR</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">2001</dateIssued></originInfo><identifier type="ISSN">1471-4892</identifier><identifier type="PII">S1471-4892(00)X0005-7</identifier><part><date>2001</date><detail type="volume"><number>1</number><caption>vol.</caption></detail><detail type="issue"><number>5</number><caption>no.</caption></detail><extent unit="issue-pages"><start>437</start><end>546</end></extent><extent unit="pages"><start>482</start><end>490</end></extent></part></relatedItem><identifier type="istex">E322701CE07DFA8A0DF19075A00CA8FD6F0E9CA4</identifier><identifier type="ark">ark:/67375/6H6-2R3399BL-9</identifier><identifier type="DOI">10.1016/S1471-4892(01)00084-4</identifier><identifier type="PII">S1471-4892(01)00084-4</identifier><accessCondition type="use and reproduction" contentType="copyright">©2001 Elsevier Science Ltd</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource><recordOrigin>Elsevier Science Ltd, ©2001</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-2R3399BL-9/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A21 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000A21 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:E322701CE07DFA8A0DF19075A00CA8FD6F0E9CA4
|texte= Therapeutic options for the management of influenza
}}
| This area was generated with Dilib version V0.6.33. |  |